目的　探讨CTAP时肝脏呈现斑片状增强的发生率及其与脾脏大小的关系。方法　对 2 1 9例原发性肝癌病人进行了CTAP检查 ,并根据结果将病人分为 3组 :肝脏呈不均一斑片状增强 (第 1组 ) ,肝脏增强均一但增强程度普遍减弱 (第 2组 ) ,肝脏增强均一对比良好 (第 3组 )。根据CT测量病人脾脏大小 ,分别比较各组脾脏大小与肝脏增强方式及程度的关系。结果　第 1组 1 0例 (4.6 % ) ,第 2组 1 6例 (7.3 % ) ,第 3组 1 93例 (88.1 % )。第 1组 ,第 2组及第 3组脾脏体积分别为 (588.3± 331 .5)cm3,(883 .2±2 96 .5)cm3和 (474.4± 2 75 .0 )cm3。第 1组与第 3组脾脏大小无显著性差异 ,而第 2组与第 3组脾脏大小具有显著性差异。结论　CTAP时肝脏呈现斑片状增强的发生率为 4 .6 %。呈现斑片状增强与脾脏大小不具有必然联系 ,而脾脏大小与肝脏增强减弱密切相关 ,脾脏体积越大肝脏增强程度越弱 Objective To investigate the incidence of patchy enhancement of liver in CTAP and its relationship with the size of spleen. Methods Twenty-nine patients with primary liver cancer underwent CTAP. According to the results, the patients were divided into three groups: the liver was unevenly patchy (group 1), the liver was homogeneously enhanced but the degree of enhancement was generally weakened 2 groups), the liver enhancement was well-matched (group 3). The size of the spleen of the patients was measured by CT, and the relationship between the size of the spleen and the mode of enhancement of the liver were compared respectively. Results The first group had 10 cases (4.6%), the second group had 16 cases (7.3%) and the third group had 93 cases (88.1%). The spleen volumes in groups 1, 2 and 3 were (588.3 ± 331.5) cm3, (883.2 ± 2 96.5) cm3 and (474.4 ± 2 75.0) cm3, respectively. There was no significant difference in spleen size between group 1 and group 3, but there was significant difference between group 2 and group 3 in spleen size. Conclusions The incidence of patchy enhancement of liver in CTAP was 4.6%. Showing patchy enhancement and spleen size is not necessarily related to the size of the spleen and enhanced liver weakening is closely related to the larger the volume of the spleen, the weaker the degree of liver enhancement